FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561071036> ?p ?o ?g. }

• W2561071036 abstract "Abstract Abstract 4299 Despite extensive research in adult acute myeloid leukemia, refractory and relapsed disease remain challenging to treat. The development of CECA (cyclophosphamide, etoposide, carboplatin, cytosine arabinoside) was promising as it provided another therapeutic option for reinduction (Kornblau, et al. Leuk Lymphoma. 1998 Jan;28:371–5). In addition, in this particular subset of patients, at the time of discovery of refractory (PrR) or relapsed (Rel) disease, the next question we face relates to stem cell transplantation. Thus, the importance of achieving complete responses (CR) becomes even more imperative. However, the reported CR rate by Kornblau et al was 12% in a study including 25 patients. We believe that patients treated with CECA at our institution have greater response rates. Furthermore, there has not been any subsequent published study regarding efficacy of CECA in refractory or relapsed AML. With these questions in mind, we performed a retrospective study of adult patients at our institution with AML who have received the CECA regimen for reinduction to determine response rates and ability to proceed to stem cell transplantation. A total of 50 adult AML patients (14 PrR and 36 Rel) received CECA for reinduction between 1999 and 2009. Median age of patients is 53 (range 24–77). 18 patients (36%) overall achieved CR (defined as less than 5% blasts in a normal or hypercellular marrow lasting at least 28 days after reinduction and peripheral blood count recovery) or CRi (CR without count recovery). Of these 18 patients, 5 had PrR and 13 had Rel. The median number of induction regimens prior to CECA was 2. In the relapsed setting, the median number of days from most recent induction regimen to CECA is 140 days. Of patients who achieved CR, 11 (61%) proceeded to allogeneic stem cell transplantation. Median number of days from CECA to transplant was 65 days. Mean progression-free survival (PFS) of patients who achieved CR was 118 days. Mean overall survival (OS) is 222 days in patients who achieved CR versus 100 days in patients who did not achieve CR. Early toxicity from CECA (defined as an adverse event within 28 days from start of chemotherapy) was fairly common and included bacteremia/sepsis (n=12), fungal pneumonia (n=7), bleeding (n=5, 2 GI, 2 pulmonary, 1 intra-abdominal), acute renal failure (n=5), cutaneous fungal infections (n=2), C. difficile colitis (n=1), and mucositis (n=1). There were 4 deaths within 28 days of therapy. The CECA regimen for reinduction has activity in patients with refractory or relapsed AML, even after receiving several prior induction cycles. The key factor is the ability of CECA to facilitate stem cell transplantation in greater than half of patients who achieve CR. The toxicity profile appears to be reasonable in this population. Our institutional experience with CECA has shown promising results. Outcomes in a large population of patients and when utilized earlier in the disease course may be even greater and warrants further evaluation. Disclosures: No relevant conflicts of interest to declare." @default.
• W2561071036 created "2017-01-06" @default.
• W2561071036 creator A5001898266 @default.
• W2561071036 creator A5008762363 @default.
• W2561071036 creator A5025323115 @default.
• W2561071036 creator A5027364145 @default.
• W2561071036 creator A5031853527 @default.
• W2561071036 creator A5042100448 @default.
• W2561071036 creator A5042492175 @default.
• W2561071036 creator A5065085606 @default.
• W2561071036 creator A5073484932 @default.
• W2561071036 creator A5078899007 @default.
• W2561071036 creator A5087573996 @default.
• W2561071036 date "2011-11-18" @default.
• W2561071036 modified "2023-10-01" @default.
• W2561071036 title "CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia" @default.
• W2561071036 doi "https://doi.org/10.1182/blood.v118.21.4299.4299" @default.
• W2561071036 hasPublicationYear "2011" @default.
• W2561071036 type Work @default.
• W2561071036 sameAs 2561071036 @default.
• W2561071036 citedByCount "0" @default.
• W2561071036 crossrefType "journal-article" @default.
• W2561071036 hasAuthorship W2561071036A5001898266 @default.
• W2561071036 hasAuthorship W2561071036A5008762363 @default.
• W2561071036 hasAuthorship W2561071036A5025323115 @default.
• W2561071036 hasAuthorship W2561071036A5027364145 @default.
• W2561071036 hasAuthorship W2561071036A5031853527 @default.
• W2561071036 hasAuthorship W2561071036A5042100448 @default.
• W2561071036 hasAuthorship W2561071036A5042492175 @default.
• W2561071036 hasAuthorship W2561071036A5065085606 @default.
• W2561071036 hasAuthorship W2561071036A5073484932 @default.
• W2561071036 hasAuthorship W2561071036A5078899007 @default.
• W2561071036 hasAuthorship W2561071036A5087573996 @default.
• W2561071036 hasConcept C126322002 @default.
• W2561071036 hasConcept C141071460 @default.
• W2561071036 hasConcept C142424586 @default.
• W2561071036 hasConcept C143998085 @default.
• W2561071036 hasConcept C2776694085 @default.
• W2561071036 hasConcept C2778119113 @default.
• W2561071036 hasConcept C2778461978 @default.
• W2561071036 hasConcept C2778729363 @default.
• W2561071036 hasConcept C2781413609 @default.
• W2561071036 hasConcept C28328180 @default.
• W2561071036 hasConcept C2911091166 @default.
• W2561071036 hasConcept C54355233 @default.
• W2561071036 hasConcept C71924100 @default.
• W2561071036 hasConcept C86803240 @default.
• W2561071036 hasConcept C87355193 @default.
• W2561071036 hasConcept C90924648 @default.
• W2561071036 hasConceptScore W2561071036C126322002 @default.
• W2561071036 hasConceptScore W2561071036C141071460 @default.
• W2561071036 hasConceptScore W2561071036C142424586 @default.
• W2561071036 hasConceptScore W2561071036C143998085 @default.
• W2561071036 hasConceptScore W2561071036C2776694085 @default.
• W2561071036 hasConceptScore W2561071036C2778119113 @default.
• W2561071036 hasConceptScore W2561071036C2778461978 @default.
• W2561071036 hasConceptScore W2561071036C2778729363 @default.
• W2561071036 hasConceptScore W2561071036C2781413609 @default.
• W2561071036 hasConceptScore W2561071036C28328180 @default.
• W2561071036 hasConceptScore W2561071036C2911091166 @default.
• W2561071036 hasConceptScore W2561071036C54355233 @default.
• W2561071036 hasConceptScore W2561071036C71924100 @default.
• W2561071036 hasConceptScore W2561071036C86803240 @default.
• W2561071036 hasConceptScore W2561071036C87355193 @default.
• W2561071036 hasConceptScore W2561071036C90924648 @default.
• W2561071036 hasLocation W25610710361 @default.
• W2561071036 hasOpenAccess W2561071036 @default.
• W2561071036 hasPrimaryLocation W25610710361 @default.
• W2561071036 hasRelatedWork W2018518588 @default.
• W2561071036 hasRelatedWork W2202448220 @default.
• W2561071036 hasRelatedWork W2532949387 @default.
• W2561071036 hasRelatedWork W2554248392 @default.
• W2561071036 hasRelatedWork W2558891317 @default.
• W2561071036 hasRelatedWork W2564124230 @default.
• W2561071036 hasRelatedWork W2565709398 @default.
• W2561071036 hasRelatedWork W2569950108 @default.
• W2561071036 hasRelatedWork W2581220283 @default.
• W2561071036 hasRelatedWork W2586110350 @default.
• W2561071036 hasRelatedWork W2586736351 @default.
• W2561071036 hasRelatedWork W2979694624 @default.
• W2561071036 hasRelatedWork W2979815572 @default.
• W2561071036 hasRelatedWork W2980135434 @default.
• W2561071036 hasRelatedWork W2980815933 @default.
• W2561071036 hasRelatedWork W2991689799 @default.
• W2561071036 hasRelatedWork W3029550323 @default.
• W2561071036 hasRelatedWork W3029557132 @default.
• W2561071036 hasRelatedWork W3032754272 @default.
• W2561071036 hasRelatedWork W3143589330 @default.
• W2561071036 isParatext "false" @default.
• W2561071036 isRetracted "false" @default.
• W2561071036 magId "2561071036" @default.
• W2561071036 workType "article" @default.